Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Federal Trade Commission
Daiichi Sankyo
McKinsey
Julphar
Moodys
Deloitte
Farmers Insurance

Generated: August 21, 2018

DrugPatentWatch Database Preview

Halozyme Therap Company Profile

« Back to Dashboard

What is the competitive landscape for HALOZYME THERAP, and what generic alternatives to HALOZYME THERAP drugs are available?

HALOZYME THERAP has one approved drug.

There is one US patent protecting HALOZYME THERAP drugs.

There are eighty-two patent family members on HALOZYME THERAP drugs in twenty-five countries and eleven supplementary protection certificates in five countries.

Summary for Halozyme Therap
International Patents:82
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Halozyme Therap

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859-001 Dec 2, 2005 RX Yes Yes 7,767,429 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Halozyme Therap

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,252 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases ➤ Try a Free Trial
9,562,223 Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP) ➤ Try a Free Trial
8,431,124 Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP) ➤ Try a Free Trial
8,431,380 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof ➤ Try a Free Trial
2,015,196,623 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Halozyme Therap Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0753 Netherlands ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
0822 Netherlands ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2015031 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
138 Luxembourg ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Accenture
Deloitte
Covington
Farmers Insurance
McKesson
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.